In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Trial investigates timing of complete revascularisation for myocardial infarction

MULTISTARS AMI trial presented in a Hot Line session today at ESC Congress 2023

Coronary Intervention

Amsterdam, Netherlands – 27 Aug 2023: Immediate multivessel percutaneous coronary intervention (PCI) is non-inferior to staged multivessel PCI for reducing death and ischaemic events in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.1

Multivessel coronary artery disease is present in about half of patients with STEMI and is associated with increased risks of recurrent myocardial infarction and mortality.2-5 The COMPLETE trial demonstrated that among patients with STEMI and multivessel coronary artery disease, complete revascularisation was superior to culprit-lesion-only PCI for reducing ischaemic events and death.6 ESC guidelines state that routine revascularisation of non-infarct-related artery lesions should be considered in STEMI patients with multivessel coronary artery disease before hospital discharge.7 However, there is a lack of evidence on the optimal timing of multivessel PCI (immediate versus staged).7,8

The MULTISTARS AMI trial investigated whether immediate complete revascularisation at the time of primary PCI was non-inferior to staged (within 19 to 45 days) multivessel PCI among haemodynamically stable patients with STEMI and multivessel coronary artery disease.9

The trial included patients with acute STEMI (presenting within 24 hours of symptom onset) and multivessel coronary artery disease (defined as at least one coronary lesion with ≥70% diameter stenosis on coronary angiography based on visual estimation in a non-culprit coronary artery of ≥2.25 mm and ≤5.75 mm in diameter), who were haemodynamically stable after successful primary PCI of the infarct-related coronary artery.

Patients were randomly allocated in a 1:1 ratio to immediate or staged (within 19 to 45 days) PCI of the non-culprit lesions. The primary endpoint was a composite of all-cause death, non-fatal myocardial infarction, stroke, unplanned ischaemia-driven revascularisation, or hospitalisation for heart failure within one year after randomisation.

The trial enrolled 840 patients from 37 sites in Europe. The average age of participants was 65 years and 21.2% were women. At one year, the primary endpoint occurred in 35 patients (8.5%) in the immediate group and in 68 patients (16.3%) in the staged group (risk ratio 0.52; 95% confidence interval 0.38 to 0.72; p<0.001 for non-inferiority; p<0.001 for superiority). The median time interval from randomisation to staged procedures in the staged group was 37 (interquartile range 30-43) days.

Non-fatal myocardial infarction occurred in 8 patients (2.0%) in the immediate group and in 22 patients (5.3%) in the staged group (hazard ratio [HR] 0.36; 95% confidence interval [CI] 0.16 to 0.80), and unplanned ischaemia-driven revascularisation was performed in 17 patients (4.1%) in the immediate group and in 39 patients (9.3%) in the staged group (HR 0.42, 95%CI 0.24 to 0.74). Rates of all-cause death, stroke, and hospitalisation for heart failure did not differ between groups.

Principal investigator Dr. Barbara Stähli of the University Hospital Zurich, Switzerland, said: “MULTISTARS AMI addresses the clinically important question of the optimal timing for a complete revascularisation of patients with STEMI and multivessel coronary artery disease. The trial has implications for clinical practice, as it demonstrated that immediate PCI of non-culprit lesions is as effective and safe as a staged procedure. Results were generally consistent across prespecified key subgroups, particularly among women and men, young and older patients, and patients with or without diabetes.”



Notes to editor

ESC Press Office
Tel: +33 (0) 6 61 40 18 84

The hashtag for ESC Congress 2023 is #ESCCongress

Follow us on Twitter @ESCardioNews 


This press release accompanies both a presentation and an ESC press conference at ESC Congress 2023. It does not necessarily reflect the opinion of the European Society of Cardiology.


Funding: The trial was supported by the Investigator-Sponsored Research Program of Boston Scientific Corporation (Marlborough, MA, USA; grant number ISROTH10277).


Disclosures: B.S. has received research grants to the institution from Boston Scientific, the B. Braun Foundation, the German Center for Cardiovascular Research (DZHK), the German Heart Research Foundation, Edwards Lifesciences, the Iten-Kohaut Foundation, and the OPO Foundation.  B.S. has received consulting and speaker fees from Abbott Vascular, Abiomed, Boston Scientific, and SMT.


References and notes

1MULTISTARS AMI will be discussed during Hot Line 6 on Sunday 27 August at 16:30 to 17:30 CEST in room Amsterdam.

2Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J. 2007;28:1709-1716.

3Jensen LO, Terkelsen CJ, Horvath-Puho E, et al. Influence of multivessel disease with or without additional revascularization on mortality in patients with ST-segment elevation myocardial infarction. Am Heart J. 2015;170:70-78.

4Kober L, Engstrom T. A more COMPLETE picture of revascularization in STEMI. N Engl J Med. 2019;381:1472-1474.

5Janardhanan R, Kenchaiah S, Velazquez EJ, et al. Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. Am Heart J. 2006;152:183-189.

6Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019;381:1411-1421.

7Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39:119–177.

8Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial

Revascularization. Eur Heart J. 2019;40:87–165.

9Stahli BE, Varbella F, Schwarz B, et al. Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. Am Heart J. 2020;228:98-108.


About ESC Congress 2023

It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Amsterdam and online – from 25 to 28 August. Explore the scientific programme. More information is available from the ESC Press Office at


About the European Society of Cardiology

The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.